

Leading the world to better health

COVID-19 SARS-CoV-2 for health care workers Samuel McConkey

Samuel McConke Deputy Dean RCSI



Contents

- 1. What happened
- 2. Clinical presentation
- 3. Complications
- 4. Management interventions
- 5. Outcomes
- 6. Health-care workers
- 7. What should we do



Coronaviruses

1965 HCoV OC43 (David A Tyrrell) 1967 HCoV 229E (from bats) 2003 SARS (from bats, via palm civet) 2004 HCoV NL63 2005 HCoV HKU3 2006 MERS (from bats) 2019 SARS-CoV-2 Cause 4 -15- 35% of URTI and some LRTI and otitis media in children even in people with pre-existing antibodies More in winter and spring Epidemics every 2 or 3 years

Big virus, largest RNA genome 20k base pairs nsp12 RdRP has low error rate, nsp 10 proof reads Ribavirin does not work


Killed easily by bleach, detergents, alcohol, soap, ...

Coronavirus OC16. Proc Natl Acad Sci USA. 1967;57;933–940.



Context

- Wuhan city central China 11m people
 - In Hubei province 55m people
- Pneumonia, fever and URTI linked to a seafood market, 41 cases by 27th Dec
- Coronavirus
- Sequenced like SARS
- Increasing cases
- Spread to rest of China despite controls
- Spread to other countries
- Isolation on a cruise ship does not work
- New cases and deaths in 70 countries



Whole genome HCoV HKU' Fig. 5: Maximum ChRCoV HKU24 100 HCoV OC43 HCoV HKU1 100 Embecovirus likelihood phylogenetic Embecovirus ChRCoV HKU24 HCoV HKU1 MHV Embecovirus -HCoV OC43 ChRCoV HKU24 MHV trees of the nucleotide Ro-BatCoV GCCDC1 -HCoV OC43 **EriCoV** 100 100 BtRt-BetaCoV/GX2018 Nobecovirus EriCoV MERS-CoV sequences of the 100 Merbecovirus Ro-BatCoV HKU9 MERS-CoV - Ty-BatCoV-HKU4 Merbecovirus EriCoV v-BatCoV-HKU4 whole genome, 81 - Pi-BatCoV HKU5 97 MERS-CoV Pi-BatCoV HKU5 Ro-BatCoV HKU9 Merbecovirus 100 and S and N genes of - Ty-BatCoV-HKU4 Ro-BatCoV GCCDC1 Ro-BatCoV GCCDC1 Nobecovirus 100 - Pi-BatCoV HKU5 -BtRt-BetaCoV/GX2018 Nobecovirus BtRt-BetaCoV/GX2018 90 WHCV and related -Ro-BatCoV HKU9 Bat Hp-BetaCoV 7 Hibecovirus Bat_Hp-BetaCoV] Hibecovirus Bat Hp-BetaCoV] Hibecovirus Bat coronavirus BM48-31/BGR/2008 -Bat coronavirus BM48-31/BGR/2008 coronaviruses Bat coronavirus BM48-31/BGR/2008 94 WH-Human 1 -LYRa11 100 WH-Human 1 BtRs-BetaCoV/YN2018B Bat-SL-CoVZC45 100 100 Bat-SL-CoVZC45 Bat SARS-like CoV RsSHC014 O Bat-SL-CoVZXC21 00 Bat-SL-CoVZXC21 Bat SARS-like CoV Rs3367 BtRf-BetaCoV/JL2012 Bat SARS coronavirus HKU3 Bat SARS-like CoV WIV1 Bat coronavirus JTMC15 BtCoV/279/2005 Civet SARS CoV SZ3 BtRf-BetaCoV/HeB2013 Bat SARS CoV Rm1 100 SARS-CoV TOR2 BtRf-BetaCoV/SX2013 -BtCoV Rp/Shaanxi2011 SARS CoV BJ01 Wu, F., Zhao, S., Yu, BtCoV/273/2005 BtRf-BetaCoV/JL2012 SARS coronavirus WH20 Bat SARS CoV Rf1 Bat coronavirus JTMC15 Bat SARS-like CoV Rs4231 82 BtCoV Rp/Shaanxi2011 BtRf-BetaCoV/HeB2013 B. et al. A new Bat SARS-like CoV Rs4874 BtCoV/279/2005 BtRf-BetaCoV/SX2013 qc 8 Bat SARS-like CoV WIV16 Bat SARS CoV Rm1 BtCoV/273/2005 100 -WH-Human 1 77 - LYRa11 Bat SARS CoV Rf1 coronavirus associated Bat-SL-CoVZC45 BtCoVCp/Yunnan2011 BtRI-BetaCoV/SC2018 100-Bat-SL-CoVZXC21 70 Bat SARS CoV Rp3 BtCoV Cp/Yunnan2011 -BtRI-BetaCoV/SC2018 100 LYRa11 with human respiratory BtRs-BetaCoV/GX2013 BtCoV Rp/Shaanxi2011 100 - Bat SARS-like CoV YNLF 34C Bat SARS coronavirus HKU3 - BtCoV Cp/Yunnan2011 Sarbecovirus BtRs-BetaCoV/GX2013 Sarbecovirus 74 BtRI-BetaCoV/SC2018 Sarbecovirus disease in Bat SARS-like CoV YNLF 34C Bat SARS CoV Rp3 BtRs-BetaCoV/YN2018A BtRf-BetaCoV/HeB2013 BtRs-BetaCoV/YN2018A Bat SARS CoV Rs672 91 BtRf-BetaCoV/SX2013 BtRs-BetaCoV/YN2018C BtRs-BetaCoV/YN2013 China. Nature (2020 BtCoV/273/2005 BtRs-BetaCoV/YN2018D 100 Bat SARS-like CoV Rs4231 9 Bat SARS CoV Rf1 Bat SARS CoV Rs672 100 Bat SARS-like CoV Rs4874 BtRs-BetaCoV/GX2013 BtRs-BetaCoV/YN2018B 98 https://doi.org/10.103 Bat SARS-like CoV WIV16 Bat SARS coronavirus HKU3 Bat SARS-like CoV RsSHC014 BtRs-BetaCoV/YN2018B Bat SARS-like CoV Rs3367 Bat SARS CoV Rp3 BtRs-BetaCoV/YN2018D 96 BtCoV/279/2005 Bat SARS-like CoV WIV1 8/s41586-020-2008-3 100 Bat SARS-like CoV RsSHC014 Bat SARS CoV Rm1 Civet SARS CoV SZ3 BtRs-BetaCoV/YN2018C SARS-CoV TOR2 BtRs-BetaCoV/YN2018A 70 Bat SARS-like CoV YNLF 34C SARS CoV BJ01 BtRs-BetaCoV/YN2018C Civet SARS CoV SZ3 SARS coronavirus WH20 BtRs-BetaCoV/YN2018D 100 92 SARS-CoV TOR2 100 Bat SARS-like CoV Rs4231 Bat SARS CoV Rs672 SARS CoV BJ01 Bat SARS-like CoV Rs4874 BtRs-BetaCoV/YN2013 QC 1001 SARS coronavirus WH20 Bat SARS-like CoV WIV16 Bat SARS-like CoV Rf4092 100 BtRs-BetaCoV/YN2013 Bat SARS-like CoV Rf4092 BtRf-BetaCoV/JL2012 100 0.5 100 Bat SARS-like CoV Rf4092 0.5 0.5 95 Bat SARS-like CoV Rs3367 100 Bat coronavirus JTMC15 Bat SARS-like CoV WIV1

Case Report

Pathological findings of COVID-19 associated with acute respiratory distress syndrome



Zhe Xu*, Lei Shi*, Yijin Wang*, Jiyuan Zhang, Lei Huang, Chao Zhang, Shuhong Liu, Peng Zhao, Hongxia Liu, Li Zhu, Yanhong Tai, Changqing Bai, Tingting Gao, Jinwen Song, Peng Xia, Jinghui Dong, Jingmin Zhao, Fu-Sheng Wang

Since late December, 2019, an outbreak of a novel coronavirus disease (COVID-19; previously known as 2019-nCoV)¹² was reported in Wuhan, China,² which has subsequently affected 26 countries worldwide. In general, COVID-19 is an acute resolved disease but it can also be deadly, with a 2% case fatality rate. Severe disease onset might result in death due to massive alveolar damage and progressive respiratory failure.^{2,3} As of Feb 15, about 66580 cases have been confirmed and over 1524 deaths. However, no pathology has been reported due to barely accessible autopsy or biopsy.^{2,3} Here, we investigated the pathological characteristics of a patient who died from severe infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by obtaining biopsy samples at autopsy. This study is in

A 50-year-old man was admitted to a fever clinic on Jan 21, 2020, with symptoms of fever, chills, cough, fatigue and shortness of breath. He reported a travel history to Wuhan Jan 8–12, and that he had initial symptoms of mild chills and dry cough on Jan 14 (day 1 of illness) but did not see a doctor and kept working until Jan 21 (figure 1). Chest x-ray showed multiple patchy shadows in both lungs (appendix p 2), and a throat swab sample was taken. On Jan 22 (day 9 of illness), the Beijing Centers for Disease Control (CDC) confirmed by reverse real-time PCR assay that the patient had COVID-19.

He was immediately admitted to the isolation ward and received supplemental oxygen through a face mask. He was given interferon alfa-2b (5 million units twice daily,

Lancet Respir Med 2020

Published Online February 17, 2020 https://doi.org/10.1016/ S2213-2600(20)30076-X

*Contributed equally

Treatment and Research Center for Infectious Diseases (Z Xu MD, L Shi MD, J Zhang PhD, L Huang MD, C Zhang PhD, P Zhao MSc, H Liu BSc, J Song PhD, P Xia MSc, Prof F-S Wang MD), Department of Pathology and Hepatology (Y Wang PhD, S Liu MSc, L Zhu MSc, Prof Y Tai MD, T Gao BSc, Prof J Zhao MD), Department of Respiration

Symptoms									Hospital				Correspondence to: Dr Fu-Sheng Wang, Treatment
Medications	Travel in Wuhan	Work	Work	Work	Fever clinic	Day 1	Day 2	Day 3	Day 4	Day 5	Day	6	and Research Center for Infectious Diseases, The Fifth
Day of illness			1-6	7	8	9	10	11	12	13	14	÷	Medical Center of PLA General
Cough													Hospital, National Clinical Research Center for Infectious
Chills				1		1							Diseases, Beijing 100039, China fswang302@163.com
Fever (°C)				Subjective	39	37.4	36.4	37-1	37-2	36.4	36.6		or Dr Jingmin Zhao, Department of
Fatigue													Pathology and Hepatology, The Fifth Medical Center of PLA General Hospital, National
Shortness of breath						1	1		1	1			Clinical Research Center for Infectious Diseases,
						1	Me	thylpredniso	lone				Beijing 100039, China jmzhao302@163.com
						1		Moxifloxacir	1				See Online for appendix
							Lopi	inavir plus rit	ı onavir tablet	ts			
							Interferon a	llfa-2b physic	i cochemical ii	nhalation			
										Meropenem			
					Chest x-ray	SARS-CoV-2 RNA positive	Chest x-ray		Chest x-ray		Death at 18:31	Post- mortem biopsy	
	Jan 8-12	Jan 13	Jan 14-19	Jan 20	Jan 21	Jan 22	Jan 23	Jan 24	Jan 25	Jan 26	Jan 2	27	

Figure 1: Timeline of disease course according to days from initial presentation of illness and days from hospital admission, from Jan 8–27, 2020 SARS-CoV-2=severe acute respiratory syndrome coronavirus 2.




Table 1. Clinical Laboratory tests.


Measure	Reference range	Illness Day 8 Fever Clinic	Illness Day 10 Hospital Day 2	Illness Day 11 Hospital Day 3	Illness Day 12 Hospital Day 4	Illness Day 14 Hospital Day 6
Complete blood count						
White-cell count (×10^9/L)	3.97-9.15	3.19‡	2.23‡	7.07		6.28
Absolute neutrophil count (×10 ⁹ /L)	2-7	2.33‡	1.840‡	6.550		5.700
Absolute Lymphocyte count (×10^9/L)	0.8-4.0	0.66‡	0.280‡	0.340‡		0.310‡
Absolute monocyte count (×10^9/L)	0.12-1.0	0.20	0.110‡	0.160		0.250
Red-cell count (×10^12/L)	4.09-5.74	4.48	4.30	4.16		4.29
Hemoglobin (g/L)	131-172	143	135.00	134.00		134.00
Platelet count (×10^9/L)	85-303	124	154.00	188.00		205.00
Biochemical test						
Total protein (g/L)	60-83		60		55‡	56‡
Albumin (g/L)	35-55		34‡		30‡	30‡
Prealbumin (mg/L)	160-400		90‡			120‡
Alanine aminotransferase (ALT) (U/L)	5-40		69§	64§	70§	59§
Aspartate aminotransferase (AST) (U/L)	8-40		111§		83§	40
Lactate dehydrogenase (LDH) (U/L)	109-245		581§		617§	825§
Urea (mmol/L)	2.9-8.2		3.8		3.94	5.9
Creatinine(umol/L)	62-115		79		77	67
Sodium (mmol/liter)	136-145		135		135	145
Potassium (mmol/liter)	3.5-5.2		3.8		3.0‡	3.5
Chloride (mmol/liter)	93-108		97.6		98.7	109.3§
Arterial blood gas (ABG) analysis						
PH	7.35-7.45		7.5§	7.47§		7.27‡
Pressure of oxygen in arterial blood (mmHg)	80-100		63‡	74‡		28‡
Pressure of carbon dioxide in arterial blood (mmHg)	35-45		34	33‡		39
Base excess (mmol/L)	-2 - +2		3.2§	0.0		-9.1‡
Alveolar-arterial oxygen partial pressure difference (mmHg)			135.7§	331.2§		510.3§
Coagulation profile						
Prothrombin time (sec)	10.2-14.3		12.1	12.5		14.9§
International normalized ratio	0.8-1.2		1.05	1.09		1.31§
Fibrinogen (g/L)	2.0-4.0		5.28§	3.70		2.90
CRP (mg/L)	0.068-8.2	33.0§	44.3§	19.46§	19.73§	26.1§
Procalcitonin (ng/ml)	0-0.5		0.181	0.099	0.089	
Interleukin-6 (pg/ml)	0-7		18.89§	37.4§		18.25§

ABG analysis of Jan 27 was tested one hour before the patient died.


‡ The value in the patient was below normal.


§ The value in the patient was above normal.


Coronavirus cases per day by country



Except China








Geo-temporal spread of COVID-19 in China through February 11, 2020. (A) a total of 14 county-level administrative areas (hereafter counties) in Hubei Province only (inset) had reported cases as of December 31, 2019; (B) by January 10, 2020, 113 counties in 20 PLADs had reported cases with the highest prevalence still in Hubei Province; (C) nine days later, on January 20, 627 counties in 30 PLADs had reported cases and PLADs neighboring Hubei Province observed increasing prevalence; (D) by the end of January 31, 1310 counties across all 31 PLADs were affected and prevalence in the central, south, and south-central regions had risen dramatically; (E) by the end of February 11, 1,386 counties nationwide were affected and prevalence in the south-central PLADs had risen to the level of Hubei.

The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020 China CDC Weekly, 2020, 2(null) http://dx.doi.org/null RCSI Leading the world



Epidemiological curves of COVID-19 in China through February 11, 2020. (A) the epidemiological curve shows the progression of illness in the outbreak over time from December 8, 2019 to February 11, 2020. A total of 72,314 cases are shown and confirmed cases (blue) are compared to suspected cases (green), clinically diagnosed cases (yellow), and asymptomatic cases (red). The inset shows a zoomed-in view of all days in December, when total daily count remained below 24 cases; (B) the epidemiological curve shows the progression of illness in the outbreak over time from December 8, 2019 to February 11, 2020 for confirmed cases only (blue). The number of cases diagnosed each day is also shown for confirmed cases only (orange). The inset shows a zoomed-in view of all days in December, when total daily count remained below 15 cases.

The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020 China, COVID-19, Octable 2020, 2020

China CDC Weekly,2020, 2(null) http://dx.doi.org/null **TABLE 1.** Patients, deaths, and case fatality rates, as well as observed time and mortality for n=44,672 confirmed COVID-19 cases in Mainland China as of February 11, 2020.

Baseline Characteristics	Confirmed Cases, N (%)	Deaths, N (%)	Case Fatality Rate, %	Observed Time, PD	Mortality, per 10 PD
Overall	44,672	1,023	2.3	661,609	0.015
Age, years					
0-9	416(0.9)	_	_	4,383	_
10-19	549(1.2)	1(0.1)	0.2	6,625	0.002
20-29	3,619(8.1)	7(0.7)	0.2	53,953	0.001
30-39	7,600(17.0)	18(1.8)	0.2	114,550	0.002
40-49	8,571(19.2)	38(3.7)	0.4	128,448	0.003
50-59	10,008(22.4)	130(12.7)	1.3	151,059	0.009
60-69	8,583(19.2)	309(30.2)	3.6	128,088	0.024
70–79	3,918(8.8)	312(30.5)	8.0	55,832	0.056
≥ 80	1,408(3.2)	208(20.3)	14.8	18,671	0.111
Sex					
Male	22,981(51.4)	653~(63.8)	2.8	342,063	0.019
Female	21,691(48.6)	370(36.2)	1.7	319,546	0.012
Occupation					
Service industry	3,449(7.7)	23(2.2)	0.7	$54,\!484$	0.004
Farmer/laborer	9,811(22.0)	139(13.6)	1.4	137,992	0.010
Health worker	1,716(3.8)	5(0.5)	0.3	28,069	0.002
Retiree	9,193~(20.6)	472(46.1)	5.1	137,118	0.034
Other/none	20,503(45.9)	384 (37.5)	1.9	303,946	0.013
Province					

Article Contents

Abst	ract				
Intro	duc	tion	L		
Meth	ıod				
Resu	lts				
Disc	issio	n			
Ackı	lowl	edg	eme	nts	
Refe	renc	<u>es</u>			
FIG	URE	1			
FIG	URE	2			
FIG	URE	3			
FIG	URE	4			
TAB	LE1	_			
TAB	LE2	2			
			_	_	
Get	Cit	ati	on		P
_				_	
A .		3.5			
Art	icle	М	etr	lCS	
Artic	le Vi	iews	(466)	(34)	

PDF Downloads(2795)

Related

TOVINCE						
Hubei	33,367(74.7)	979~(95.7)	2.9	496,523	0.020	
Other	$11,305\ (25.3)$	44(4.3)	0.4	165,086	0.003	Article Conte
Wuhan-related exposure [*]						
Yes	31,974(85.8)	853(92.8)	2.7	$486,\!612$	0.018	Abstract
No	5,295(14.2)	66(7.2)	1.2	71,201	0.009	Introduction
Missing	7,403	104	2.8	103,796	0.010	Method Results
Comorbid condition ^{\dagger}						Discussion
Hypertension	2,683(12.8)	161(39.7)	6.0	42,603	0.038	Acknowledgemen
Diabetes	1,102(5.3)	80 (19.7)	7.3	17,940	0.045	
Cardiovascular disease	873(4.2)	92 (22.7)	10.5	13,533	0.068	References
Chronic respiratory disease	511(2.4)	32(7.9)	6.3	8,083	0.040	FIGURE1
Cancer (any)	107(0.5)	6(1.5)	5.6	1,690	0.036	FIGURE2
None	15,536(74.0)	133(32.8)	0.9	242,948	0.005	FIGURE3 FIGURE4
Missing	23,690(53.0)	617(60.3)	2.6	331,843	0.019	TABLE1
Case severity [§]						TABLE2
Mild	$36,160\ (80.9)$	_	_	_	-	
Severe	6,168(13.8)	_	_	_	_	Get Citation
Critical	2,087(4.7)	1,023(100)	49.0	31,456	0.325	
Missing	257(0.6)	_	_	_	_	Article Metri
Period (by date of onset)						
Before Dec 31, 2019	104(0.2)	15(1.5)	14.4	5,142	0.029	Article Views(466
Jan 1–10, 2020	653(1.5)	102(10.0)	15.6	21,687	0.047	PDF Downloads(2
Jan 11–20, 2020	5,417(12.1)	310(30.3)	5.7	130,972	0.024	
Jan 21–31, 2020	26,468(59.2)	494 (48.3)	1.9	416,009	0.012	Related
After Feb 1, 2020	12,030 (26.9)	102(10.0)	0.8	87,799	0.012	

Effects of SARS 2

Chinese CDC report n=55,000

88% Fever 68% Dry cough 38% Fatigue 33% Sputum SOB 18% Sore throat 13% HA 13% Myalgia/arthralgia 14% Chills 11% N,V 5% Diarrhoea 4% Rarely completely asymptomatic 80% of cases were mild, Sats >93%
14% severe PaO2/FiO2 <300mmHg
6% critical with respiratory failure, occasionally other organ failure
Crude Fatality rate was 3.8% dropped to 0.7% later with better care
Outside Wuhan 0.7%

Time to recovery – 2 weeks if mild 3-6 weeks if severe Onset - > severe takes 1 week Onset -> death takes 2 – 8 weeks





Effects of SARS 2

SOFA scores

Lung dysfunction 20%



Acute Kidney Injury <1%



Heart A few



Delerium

??



Liver failure ??



Coagulopathy A few





What do I think will happen?

On 2 Feb 2020: a range of possible expectations



Best case – lots of suspected cases and no or few confirmed no clusters, no transmission

Expected scenario - like the Dec 2019 influenza

Worst case- 20% attack ratio and 2% mortality, 20,000 deaths



What do I think will happen?

Today 5 March 2020

Best case– very many clusters and some uncontrolled community transmission in Ireland leading to something like the Dec 2019 seasonal influenza, widespread economic and social disruption

Expected scenario – like the 1918/19 Spanish influenza, a once in a century event, overwhelming of the health care system, massive economic disruption

Worse case- 80% attack ratio and 3.8% mortality challenge to our free liberal democratic government long term change in our way of life





What can we do for patients?

Artificial homeostasis for SARS-CoV-2

Measure and monitor, and intervene to maintain metabolic parameters within normal range



Oxygen

H2O, H+, CO2, blood pressure, renal function, glucose, Na, K, Cl, Ca, Mg, albumin, PO4, red cells, platelets, polymorphs, skin care, venous embolism prophylaxis, stress ulcer prevention, enteral nutrition, chemical sedation, replace clotting factors.

Minimise onwards transmission to staff and other patients (Pods)

Clinical trials of RNA polymerase and protease inhibitors



The unknowns

What is the death rate for COVID19? What is the R0, under different levels of social distancing?

How can we rapidly scale up health care services? Can we reach 99-100% compliance about how to don, to doff, to label, clean and bag samples?

The extent of asymptomatic transmission? Is there strong evidence that closing school works? Does closing factories work? Does closing public transport work? Closing airports? Staying at home? Balancing and predicting the economic impact of above



What can we do as a community?

Copy the Chinese Government

Very thorough compliant identification, contact tracing, self isolation at home for 14 days e.g. 900 teams of 5 people in each, digital records

Scale up Health-care to look after the sick and prevent in-hospital transmission – re-training

Social distancing, >2m or outside

Maintain essential services- water, food, electricity, internet, GPS, phones, media, healthcare, security, governance, culture



What can we do as individuals ?

Listen to Tony Holohan, CMO hse.ie

If unwell and travelled from an affected area selfisolate and call GP

If well read the HSE, HPSC and DFA advice

Respiratory etiquette, tissue, bin, wash hands

Re-assure, reaffirm and teach others

Travel with DFA advice

Enjoy life, sports, music, dancing, friends, family, culture, volunteering



In hospitals

Contingency planning

Plan for safe assessment of referred patients

- 20 per day (have done)
- 200 per day (can do)
- 2000 per day?

Plan for safe effective care for people with respiratory failure

- 10 in our hospital (can do)
- 100 in our hospital (can do)
- 1000 in our region?
- 10,000 in our region?

Plan for safe effective mechanical ventilation

- 10 in our hospital (can do)
- 50 in our hospital (can do)
- 200 in our region?
- 3000 in our region?

Build more, re-purpose, re-designate spaces Recruit, train and organise staff



Plan for the worst

Attack ratio of 80% == 4 million in Ireland 20% respiratory failure == 800,000 Perhaps over 1 or 2 months Hopefully over 6 – 12 - 24 months 6% mechanical ventilation = 240,000



Research

Meticulous data collection

Audit of artificial homeostasis for SARS-2

Clinical trials of existing protease inhibitors

Clinical trials of new RdRP, remdesivir

Vaccine development

Artificial Intelligence using mobile phone location data for contact tracing

Behavioural science understanding of how best to teach staff, relatives and patients

Social determinants of health





Nationally

All government multi-sectoral approach Detailed, tested business continuity plans for all essential services Re-allocation of staff to contact tracing Balance the social and economic costs of distancing Create surge capacity for identification and testing Create surge capacity in hospitals for ID care Create surge capacity in hospitals for ICU care Use fast AI for contact tracing with GPS data Legal controls of mass gatherings Who and how to enforce a cordon sanitaire Support factories to make gowns, masks gloves Support the farmers to feed us and export Support pharma to make vaccines, anti-virals and O2 Identify critical areas which are struggling and assist Legal changes that are needed Decisions about staying at home, enforcement, support

Decisions about closing transport, enforcement, support

own continuity plans – nominated designate

- working from home, VC, TC, email
- use of IT
- analysis and mitigation of supply chain
- analysis and mitigation of sales
- treasury and financing
- travel, trade and export disruptions
- managing internal communications



Social cohesion

To do this we need wide social cohesion and cooperation

To achieve social cohesion and co-operation we need widespread social trust

To achieve social trust we need a widespread perception of social equality

To achieve a perception of social equality we need social equality

To achieve social equality we need a basic living wage for all, access to pre-school, 1st, 2nd 3rd level education for all, access to health care and affordable housing







Leading the world to better health







Thank you

Samuel McConkey smcconkey@rcsi.ie



Centuries of discipline in independent education, discovery, & responsibility for human health

